• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Leo Pharma (Group)

LEO Pharma is specialised in dermatology (primarily psoriasis and skin infections) and critical care (hemostasis and nephrology). In 2005 LEO Pharma had revenues of MEUR 652 with profit before tax of MEUR 337. The equity position in 2005 was MEUR 1,741. LEO Pharma is a Pan-European company with subsidiaries in most European countries as well as in Canada, Middle East, Far East and Latin America. LEO Pharma products are sold in 90 countries and the company employs 3,000 people. LEO Pharma is 100% owned by the LEO Foundation. The sole purpose of the Foundation is to run LEO Pharma as an independent pharmaceutical company *

 

	Start	1990-01-01 existent
	End	1994-07-01 existent
	Industry	pharmaceutical
	Industry 2	dermatic
	Person	Aabo, Gitte (Leo Pharma 201511 CEO)
	Person 2	Kronborg, Anders (Leo Pharma 201510– EVP Global Finance, IT + Legal before Kinnevik Investment AB)
	Region	Ballerup
	Country	Denmark
	Street	55 Industriparken
	City	2750 Ballerup
	Tel	+45-44-945888
		Address record changed: 2018-07-24
Basic data	Employees	n. a.
		* Document for �About Section�:
		Record changed: 2017-06-27

Advertisement

More documents for Leo Pharma (Group)

• [1] Evotec AG. (12/4/18). "Press Release: Evotec and Leo Pharma Form Drug Discovery Alliance Targeting Dermatological Conditions". Hamburg & Ballerup....
• [2] Leo Pharma A/S. (11/20/18). "Press Release: Leo Pharma and PellePharm Announce $760 Million Collaboration to Advance Innovative Therapies for Rare Skin Diseases". Ballerup & San Francisco, CA....
• [3] Argen-X N.V. (Argenx). (4/12/18). "Press Release: Argenx to Receive Third Preclinical Milestone Payment from Collaboration with Leo Pharma". Breda & Ghent....
• [4] Leo Pharma A/S. (7/20/17). "Press Release: LEO Pharma Receives Marketing Authorisation for Kyntheum (brodalumab), a New Biologic for the Treatment of Moderate-to-severe Plaque Poriasis in the European Union". Ballerup....
• [5] Argen-X N.V. (Argenx). (6/20/17). "Press Release: Argenx Receives Second Preclinical Milestone Payment in Collaboration with Leo Pharma". Breda & Ghent....
• [6] AstraZeneca plc. (5/19/17). "Press Release: Brodalumab Receives Positive CHMP Opinion for the Treatment of Adult Patients with Moderate-to-severe Plaque Psoriasis"....
• [7] Leo Pharma A/S. (3/3/17). "Press Release: Leo Pharma Announces Positive Results from Phase 2b Clinical Study for Tralokinumab in Atopic Dermatitis". Ballerup....
• [8] MorphoSys AG. (11/2/16). "Press Release: MorphoSys and Leo Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatology"....
• [9] AstraZeneca plc. (7/1/16). "Press Release: AstraZeneca Enters Licensing Agreements with LEO Pharma in Skin Diseases"....
• [10] Leo Pharma A/S. (11/11/15). "Press Release: LEO Pharma to Acquire Global Dermatology Portfolio from Astellas". Ballerup....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Contact  |  The use of this website requires to accept the disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.